- Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Merck to discontinue KEYNOTE-598 trial of oncology therapy

Merck’s latest decision is followed by the recommendation from an independent DMC. Credit: Copyright © 2009-2020 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A. All rights reserved.